Bedrijfsoverzicht
Zentek Ltd. is a specialized entity headquartered in Canada that focuses on the research and development of graphene and related nanomaterials. Within the healthcare sector, specifically the medical instruments and supplies industry, the company applies this technology to create graphene-based antimicrobial coatings under the ZenGUARD brand, alongside developing surgical masks, HVAC filters, personal protective equipment, and rapid detection points. The organization currently employs 18 individuals to support its operations and product development initiatives. With a market capitalization of $58.80M and trailing twelve-month revenue of $942,877, the company operates on a micro-cap scale relative to broader market peers. These financial metrics indicate that Zentek Ltd. functions as a high-risk, early-stage venture within its niche, where the significant disparity between its market valuation and annual revenue suggests the market is pricing in substantial future growth potential rather than current profitability.
Financiële gezondheid
The company reported annual revenue of $942,877, yet this top-line figure is offset by a net income loss of $-8,081,361 and an EBITDA of $-8,374,869. The substantial gap between the modest revenue figure and the massive negative net income reveals a highly aggressive cost structure or significant one-time expenses that are not covered by current sales volumes. Free cash flow stands at $-1,694,322, which indicates that the company is burning cash to fund its R&D and expansion efforts, thereby limiting its immediate financial flexibility and reliance on external capital sources. Margin analysis shows a gross margin of 50.5%, suggesting that the core products retain significant value after direct costs, while the operating margin of -4155.2% and profit margin of 0.0% highlight severe operational inefficiencies or non-operating losses impacting the bottom line. On the balance sheet, cash holdings of $1.80M are slightly less than total debt of $1.90M, resulting in a debt-to-equity ratio of 15.40, which characterizes the company as highly leveraged with a precarious capital structure. The current ratio of 1.00 indicates that the company holds just enough current assets to cover its current liabilities, signaling a tight liquidity position with no buffer for short-term financial shocks. Furthermore, the return on equity of -56.6% and return on assets of -30.1% demonstrate that management has not yet generated positive returns on shareholder capital or the asset base, reflecting the inherent risks associated with a loss-making entity in a volatile market.
Waarderingsbeoordeling
Valuation metrics for Zentek Ltd. are difficult to interpret using traditional multiples, as the P/E Ratio (TTM) and Forward P/E are both N/A due to the absence of positive earnings. The price-to-book ratio is calculated at 6.61, which implies that the market values the company at a significant premium over its net book value, a common characteristic for firms in emerging technologies where intangible assets may not be fully reflected on the balance sheet. Alternative valuation measures such as the price-to-sales ratio of 62.37 and an EV/EBITDA of -7.03 further underscore the speculative nature of the investment, as the negative multiple reflects the company's inability to generate positive operating cash flow relative to its enterprise value. The stock price has fluctuated within a 52-week range defined by a high of $1.84 and a low of $0.50. To determine the current price position relative to this historical range, one must note that the current share price sits between these extremes, reflecting the volatility inherent in small-cap healthcare stocks. The beta of 0.35 indicates that the stock exhibits low price volatility relative to the broader market, moving less than half as much as the general index, which may offer a degree of stability despite the fundamental financial distress.
Growth & Income
Revenue growth year-over-year has accelerated significantly to 73.1%, demonstrating a rapid expansion in sales volume or market penetration for its graphene products. Earnings growth is listed as N/A because the company has not achieved profitability, meaning there is no earnings trajectory to compare against the revenue expansion. The absence of dividend income is confirmed by a dividend yield of N/A and a payout ratio of 0.0%, which signifies that the company does not distribute profits to shareholders but instead retains all resources to fund its ongoing research and development. Consequently, Zentek Ltd. operates as a non-dividend payer that reinvests its limited earnings and cash reserves into business growth rather than providing income to investors. The overall growth and income profile presents a classic high-risk scenario where substantial revenue expansion occurs alongside deep losses, offering potential capital appreciation opportunities but providing no current income stream or earnings stability.